Tag - Zylö Therapeutics

Zylö Receives $225,000 NIH Grant to Further Develop Nitric-Oxide-Releasing Z-pods™ to Treat Erectile Dysfunction

Ziad2022-11-25T14:03:26-05:00 Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $225,000 Small Business Technology Transfer grant. The grant was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (a division of the NIH) to further develop Zylö’s proprietary nitric-oxide topical delivery system (called Z-pods™); and the project is titled, “Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors.” Read more >>

Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment

Ziad2022-11-25T14:03:26-05:00 The study is being conducted in partnership with Zylö Therapeutics to confirm that topical administration of Hoth's AEA-loaded Z-pods™ inhibits the development of CLE lesions in a well-established animal model of lupus. Test protocol requires weekly scoring and a treatment period of 10 weeks after the initial lesions are recorded. Read more >>

Dr. Adam Friedman to Present Keynote at Dermatology Fall Update

Ziad2022-11-25T14:03:26-05:00 Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that its scientific advisor, Adam Friedman MD, will serve as a keynote speaker at the Dermatology Update 2019 Fall Meeting in Toronto on November 7. Read more >>

Zylö Therapeutics Closes $4 Million Series A Financing

Ziad2022-11-25T14:03:26-05:00 Zylö Therapeutics Inc., dedicated to developing a transformational topical delivery platform, announced that on September 21, 2019, it effected a closing of its Series A financing through the sale of $4 million of Series A preferred shares. Read more >>